id,filing_uuid,filing_type,registrant_name,registrant_id,client_name,filing_year,filing_period,issue_code,specific_issues,government_entities,income_amount,expense_amount,is_no_activity,is_termination,received_date
1347683,751ebd2d-e086-4c61-8bff-ca32dd4edd63,Q4,THE INGRAM GROUP LLC,400577737,PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA),2012,fourth_quarter,CPT,"Issues related to the Patent Reform Act of 2011, S.23.","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2013-01-19T22:13:20.820000-05:00
1347684,751ebd2d-e086-4c61-8bff-ca32dd4edd63,Q4,THE INGRAM GROUP LLC,400577737,PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA),2012,fourth_quarter,HCR,"Issues related to the implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) of 2012, Public Law No: 112-144.","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2013-01-19T22:13:20.820000-05:00
1347685,751ebd2d-e086-4c61-8bff-ca32dd4edd63,Q4,THE INGRAM GROUP LLC,400577737,PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA),2012,fourth_quarter,MMM,"Issues related to the Patient Protection and Affordable Care Act, P.L. 111-148: Medicare issues related to the Independent Payment Advisory Board (IPAB), Medicare funding issues, P.L. 112-25, the Budget Control Act of 2011 and the American Taxpayer Relief Act of 2012, H.R. 8.","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2013-01-19T22:13:20.820000-05:00
1347686,751ebd2d-e086-4c61-8bff-ca32dd4edd63,Q4,THE INGRAM GROUP LLC,400577737,PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA),2012,fourth_quarter,PHA,"Issues related to pharmaceutical importation, generic drug pricing and the FAIR Generics Act, S.1882.","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2013-01-19T22:13:20.820000-05:00